8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Jan 30, 2024)

Filed January 30, 2024For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on January 29, 2024, to furnish a press release detailing its fourth-quarter and full-year 2023 financial results, released on January 30, 2024. This filing serves as the primary communication channel for these key financial performance metrics. Investors should refer to the furnished press release (Exhibit 99) for detailed information on the company's operational and financial condition during the reported periods. While the 8-K itself does not contain the financial figures, it directs investors to the press release for comprehensive data. This includes revenue, earnings, and any forward-looking statements or guidance provided by the company. The filing reiterates that the information furnished under Item 2.02 is not considered 'filed' for the purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal implications as a formally filed document.

Key Highlights

  • 1Pfizer released its Q4 and Full-Year 2023 financial results via a press release on January 30, 2024.
  • 2The 8-K filing on January 29, 2024, serves as notification and furnishes this press release as Exhibit 99.
  • 3Investors can access detailed financial performance and operational updates within the press release.
  • 4The filing incorporates the press release by reference for information on results of operations and financial condition.
  • 5Information furnished under Item 2.02 is not deemed 'filed' under Section 18 of the Exchange Act, limiting legal liability for this specific disclosure.
  • 6The accompanying Exhibit Index confirms the press release and a Cover Page Interactive Data File (XBRL) are part of the filing.

Frequently Asked Questions

Pfizer's Q4 and Full-Year 2023 financial results can be found in the press release dated January 30, 2024, which is furnished as Exhibit 99 in this 8-K filing.

This 8-K filing primarily serves to officially release Pfizer's financial performance for the fourth quarter and the full year of 2023. It directs investors to the accompanying press release for the detailed financial information and operational updates.

No, the information furnished under Item 2.02, including the press release, is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not subject the company to the same liabilities as formally filed documents, except where expressly stated otherwise in future filings.

In addition to the press release (Exhibit 99), the filing includes the Cover Page Interactive Data File (XBRL) with embedded tags.